Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015000LC2
Tue, 02.12.2025
Mainz BioMed N.V.
DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio
DNA-based Colorectal Cancer Screening as a Home Test
BERKELEY, US, MAINZ and BERLIN, Germany – December 02, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer,today announced that [ … ]
Tue, 18.11.2025
Mainz BioMed N.V.
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador
BERKELEY, US and MAINZ, Germany – November 18, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Compa [ … ]
Wed, 12.11.2025
Mainz BioMed N.V.
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
BERKELEY, US and MAINZ, Germany – November 12, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of [ … ]
Mon, 10.11.2025
Mainz BioMed N.V.
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
BERKELEY, US and MAINZ, Germany – November 10, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announ [ … ]
Wed, 15.10.2025
Mainz BioMed N.V.
Mainz Biomed to Attend 2025 Maxim Growth Summit
BERKELEY, US and MAINZ, Germany – October 15, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place Oct [ … ]
Wed, 08.10.2025
Mainz BioMed N.V.
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study Demonstrated a Sensitivity of 100% and Specificity of 95%
BERKELEY, US and MAINZ, Germany – October 8, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in [ … ]
Tue, 30.09.2025
Mainz BioMed N.V.
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
BERKELEY, US and MAINZ, Germany – September 30, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its particip [ … ]
Tue, 23.09.2025
Mainz BioMed N.V.
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Company Provides Update on eAArly DETECT 2 Study
BERKELEY, US and MAINZ, Germany – September 23, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to ann [ … ]
Tue, 02.09.2025
Mainz BioMed N.V.
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
BERKELEY, US and MAINZ, Germany – September 2, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official registration wit [ … ]
Wed, 13.08.2025
Mainz BioMed N.V.
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
BERKELEY, US and MAINZ, Germany – August 13, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal cancer (CRC) [ … ]
